Oral administration of nano-emulsion curcumin in mice suppresses inflammatory-induced NFkB signaling and macrophage migration

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Young, Nicholas A ^a   Bruss, Michael S ^a   Gardner, Mark ^a   Willis, William L ^a   Mo, Xiaokui ^b   Valiente, Giancarlo R ^a   Cao, Yu ^a   Liu, Zhongfa ^a,c   Jarjour, Wael N ^a   Wu, Lai Chu ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b Center for Biostatistics   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CURCUMIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; THIOGLYCOLIC ACID; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA; ANTIINFLAMMATORY AGENT; DRUG CARRIER; EMULSION;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MACROPHAGE MIGRATION INHIBITION; MALE; MONOCYTE; MOUSE; NANOEMULSION; NONHUMAN; PERITONITIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CELL MOTION; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; EMULSION; IMMUNOLOGY; MACROPHAGE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL LINE; CELL MOVEMENT; CURCUMIN; DRUG CARRIERS; EMULSIONS; HUMANS; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MICE, INBRED BALB C; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 84925365060     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111559     Document Type: Article

References (40)

1. Goel A, Kunnumakkara AB, Aggarwal BB (2008) Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol 75: 787-809.
2. Chandrasekaran AN, Radhakrishna B (1995) Rheumatoid arthritis and connective tissue disorders: India and South-East Asia. Baillieres Clin Rheumatol 9: 45-57.
3. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, et al. (2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or premalignant lesions. Anticancer Res 21: 2895-2900.
4. Zhou H, Beevers CS, Huang S (2011) The targets of curcumin. Curr Drug Targets 12: 332-347.
5. Kowluru RA, Kanwar M (2007) Effects of curcumin on retinal oxidative stress and inflammation in diabetes. Nutr Metab (Lond) 4: 8.
6. Parodi FE, Mao D, Ennis TL, Pagano MB, Thompson RW (2006) Oral administration of diferuloylmethane (curcumin) suppresses proin flammatory cytokines and destructive connective tissue remodeling in experimental abdominal aortic aneurysms. Ann Vasc Surg 20: 360-368.
7. Lubbad A, Oriowo MA, Khan I (2009) Curcumin attenuates inflammation through inhibition of TLR-4 receptor in experimental colitis. Mol Cell Biochem 322: 127-135.
8. Holt PR, Katz S, Kirshoff R (2005) Curcumin therapy in inflammatory bowel disease: A pilot study. Dig Dis Sci 50: 2191-2193.
9. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, et al. (2006) Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4: 1502- 1506.
10. Shakibaei M, John T, Schulze-Tanzil G, Lehmann I, Mobasheri A (2007) Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: Implications for the treatment of osteoarthritis. Biochem Pharmacol 73: 1434-1445.
11. Wahlstrom B, Blennow G (1978) A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol (Copenh) 43: 86-92.
12. Lao CD, Ruffin MTt, Normolle D, Heath DD, Murray SI, et al. (2006) Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 6: 10.
13. Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, et al. (2011) Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila) 4: 354-364.
14. Zhongfa L, Chiu M, Wang J, Chen W, Yen W, et al. (2012) Enhancement of curcumin oral absorption and pharmacokinetics of curcuminoids and curcumin metabolites in mice. Cancer Chemother Pharmacol 69: 679-689.
15. Young NA, Friedman AK, Kaffenberger B, Rajaram MV, Birmingham DJ, et al. (2013) Novel estrogen target gene ZAS3 is overexpressed in systemic lupus erythematosus. Mol Immunol 54: 23-31.
16. Verbeke G, Molenberghs G (2000) Linear mixed models for longitudinal data. New York: Springer., 568 p. p.
17. Hsu JC (1996) Multiple comparisons : Theory and methods. London: Chapman & Hall. xiv, 277 p., 274 p. of plates p.
18. Meng Z, Yan C, Deng Q, Gao DF, Niu XL (2013) Curcumin inhibits LPSinduced inflammation in rat vascular smooth muscle cells in vitro via ROSrelative TLR4-MAPK/NF-kappaB pathways. Acta Pharmacol Sin 34: 901-911.
19. Kirschning CJ, Wesche H, Merrill Ayres T, Rothe M (1998) Human toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide. J Exp Med 188: 2091-2097.
20. Yamamoto Y, Harashima A, Saito H, Tsuneyama K, Munesue S, et al. (2011) Septic shock is associated with receptor for advanced glycation end products ligation of LPS. J Immunol 186: 3248-3257.
21. Zhong F, Chen H, Han L, Jin Y, Wang W (2011) Curcumin attenuates lipopolysaccharide-induced renal inflammation. Biol Pharm Bull 34: 226-232.
22. Jacob A, Chaves L, Eadon MT, Chang A, Quigg RJ, et al. (2013) Curcumin alleviates immune-complex-mediated glomerulonephritis in factor-H-deficient mice. Immunology 139: 328-337.
23. Pan MH, Lin-Shiau SY, Lin JK (2000) Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IkappaB kinase and NFkappaB activation in macrophages. Biochem Pharmacol 60: 1665-1676.
24. Pae HO, Jeong SO, Kim HS, Kim SH, Song YS, et al. (2008) Dimethoxycurcumin, a synthetic curcumin analogue with higher metabolic stability, inhibits NO production, inducible NO synthase expression and NF-kappaB activation in RAW264.7 macrophages activated with LPS. Mol Nutr Food Res 52: 1082-1091.
25. Wan H, Coppens JM, van Helden-Meeuwsen CG, Leenen PJ, van Rooijen N, et al. (2009) Chorionic gonadotropin alleviates thioglycollate-induced peritonitis by affecting macrophage function. J Leukoc Biol 86: 361-370.
26. Kipari T, Watson S, Houlberg K, Lepage S, Hughes J, et al. (2009) Lymphocytes modulate peritoneal leukocyte recruitment in peritonitis. Inflamm Res 58: 553-560.
27. Verderio P, Bonetti P, Colombo M, Pandolfi L, Prosperi D (2013) Intracellular drug release from curcumin-loaded PLGA nanoparticles induces G2/M block in breast cancer cells. Biomacromolecules 14: 672-682.
28. Kunwar A, Barik A, Pandey R, Priyadarsini KI (2006) Transport of liposomal and albumin loaded curcumin to living cells: An absorption and fluorescence spectroscopic study. Biochim Biophys Acta 1760: 1513-1520.
29. Li X, Liu X (2005) Effect of curcumin on immune function of mice. J Huazhong Univ Sci Technolog Med Sci 25: 137-140.
30. Carlsen H, Moskaug JO, Fromm SH, Blomhoff R (2002) In vivo imaging of NFkappa B activity. J Immunol 168: 1441-1446.
31. Prasad S, Tyagi AK, Aggarwal BB (2014) Recent Developments in Delivery, Bioavailability, Absorption and Metabolism of Curcumin: The Golden Pigment from Golden Spice. Cancer Res Treat 46: 2-18.
32. Zhu HT, Bian C, Yuan JC, Chu WH, Xiang X, et al. (2014) Curcumin attenuates acute inflammatory injury by inhibiting the TLR4/MyD88/NFkappaB signaling pathway in experimental traumatic brain injury. J Neuroinflammation 11: 59.
33. Kim DC, Lee W, Bae JS (2011) Vascular anti-inflammatory effects of curcumin on HMGB1-mediated responses in vitro. Inflamm Res 60: 1161-1168.
34. Fu Y, Gao R, Cao Y, Guo M, Wei Z, et al. (2014) Curcumin attenuates inflammatory responses by suppressing TLR4-mediated NF-kappaB signaling pathway in lipopolysaccharide-induced mastitis in mice. Int Immunopharmacol.
35. Luster AD, Rothenberg ME (1997) Role of the monocyte chemoattractant protein and eotaxin subfamily of chemokines in allergic inflammation. J Leukoc Biol 62: 620-633.
36. Boekhoudt GH, Guo Z, Beresford GW, Boss JM (2003) Communication between NF-kappa B and Sp1 controls histone acetylation within the proximal promoter of the monocyte chemoattractant protein 1 gene. J Immunol 170: 4139-4147.
37. Karlstetter M, Lippe E, Walczak Y, Moehle C, Aslanidis A, et al. (2011) Curcumin is a potent modulator of microglial gene expression and migration. J Neuroinflammation 8: 125.
38. Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, et al. (2004) Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 31: 645-648.
39. Ngwuluka N, Pillay V, Du Toit LC, Ndesendo V, Choonara Y, et al. (2010) Levodopa delivery systems: Advancements in delivery of the gold standard. Expert Opin Drug Deliv 7: 203-224.
40. Dhanasekaran S, Biswal BK, Sumantran VN, Verma RS (2013) Augmented sensitivity to methotrexate by curcumin induced overexpression of folate receptor in KG-1 cells. Biochimie 95: 1567-1573.